Related Experiment Video
Updated: May 18, 2026

Comprehensive Profiling of Dopamine Regulation in Substantia Nigra and Ventral Tegmental Area
Published on: August 10, 2012
Modulation of methamphetamine-induced nitric oxide production by neuropeptide Y in the murine striatum
Haley L Yarosh1, Jesus A Angulo
1Hunter College of the City University of New York, Department of Biological Sciences, 695 Park Avenue, 10021 New York, NY, USA.
Abstract:
Methamphetamine (METH) is a potent stimulant that induces both acute and long-lasting neurochemical changes in the brain including neuronal cell loss. Our laboratory demonstrated that the neuropeptide substance P enhances the striatal METH-induced production of nitric oxide (NO). In order to better understand the role of the striatal neuropeptides on the METH-induced production of NO, we used agonists and antagonists of the NPY (Y1R and Y2R) receptors infused via intrastriatal microinjection followed by a bolus of METH (30 mg/kg, ip) and measured 3-NT immunofluorescence, an indirect index of NO production. One striatum received pharmacological agent while the contralateral striatum received aCSF and served as control. NPY receptor agonists dose dependently attenuated the METH-induced production of striatal 3-NT. Conversely, NPY receptor antagonists had the opposite effect. Moreover, METH induced the accumulation of cyclic GMP and activated caspase-3 in approximately 18% of striatal neurons, a phenomenon that was attenuated by pre-treatment with NPY2 receptor agonist. Lastly, METH increased the levels of striatal preproneuropeptide Y mRNA nearly five-fold 16 h after injection as determined by RT-PCR, suggesting increased utilization of the neuropeptide. In conclusion, NPY inhibits the METH-induced production of NO in striatal tissue. Consequently, production of this second messenger induces the accumulation of cyclic GMP and activated caspase-3 in some striatal neurons, an event that may precede the apoptosis of some striatal neurons.
Insights
Neuropeptide Y (NPY) inhibits methamphetamine (METH)-induced nitric oxide (NO) production in the striatum. This neuroprotective effect may prevent METH-induced neuronal damage and apoptosis.
Area of Science:
- Neuroscience
- Pharmacology
- Neurochemistry
Background:
- Methamphetamine (METH) causes neurotoxicity, including neuronal cell loss.
- Substance P enhances METH-induced nitric oxide (NO) production in the striatum.
- The role of neuropeptide Y (NPY) in METH-induced NO production is not fully understood.
Purpose of the Study:
- To investigate the role of NPY receptors (Y1R and Y2R) in regulating METH-induced NO production in the striatum.
- To determine the effects of NPY receptor agonists and antagonists on METH-induced neurochemical changes.
Main Methods:
- Rats received intrastriatal microinjections of NPY receptor agonists or antagonists.
- Following microinjection, rats received a bolus of METH (30 mg/kg, ip).
- Striatal 3-nitrotyrosine (3-NT) immunofluorescence, cyclic GMP, activated caspase-3, and preproneuropeptide Y mRNA levels were measured.
Main Results:
- NPY receptor agonists dose-dependently attenuated METH-induced striatal 3-NT production.
- NPY receptor antagonists exacerbated METH-induced 3-NT production.
- METH-induced accumulation of cyclic GMP and activation of caspase-3 were attenuated by an NPY2 receptor agonist.
- METH increased striatal preproneuropeptide Y mRNA levels, indicating increased NPY utilization.
Conclusions:
- NPY inhibits METH-induced NO production in the striatum.
- NPY's inhibitory effect on NO production may mitigate METH-induced cyclic GMP accumulation and caspase-3 activation.
- These findings suggest a neuroprotective role for NPY against METH-induced neurotoxicity.
Related Concept Videos
Nitric Oxide Signaling Pathway
Drugs Affecting Neurotransmitter Synthesis
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Neurochemical Transmission: Sites of Drug Action
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...

